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e Helsinki University Hospital, Helsinki, FinlandSquamous cell carcinoma (SCC) is amajor type of solid cancer that is especially important ﬁnding since one of the major problems for TSCC
derived from squamous cells and may develop in several parts of the
body. Head and neck (HN) SCC represent a high proportion of the
total SCC cases, indeed HNSCC is the eighth most common malignancy
[1] and is a major cause of death worldwide. Sadly, HNSCC patients
have low ﬁve-year survival rate of around 50% [3]. It is unfortunate
that this percentage has not essentially improved over the last few de-
cades. This is still the challenging fact, in spite of considerable advances
in our knowledge of SCC progression, and also the introduction of new
therapies such as the use of targeted (cetuximab), and immuno
(pembrolizumab and nivolumab) therapies. These facts highlight the
need for further studies in this ﬁeld, especially to understand more
about themechanisms underlying SCC cancer progression and to reveal
novel molecules which could be targeted for therapeutic purposes.
In EBioMedicine, Zhang et al. studied the role of the R-spondin 2-
LGR4 system in tongue (T) SCC as an example of SCC both in general,
and HNSCC speciﬁcally [9]. Studying this system in TSCC is of profound
importance mainly because 1) the R-spondin 2-LGR4 system had not
been studied before in TSCC, and 2) there are conﬂicting results about
its role in other solid cancers, such as colon, breast, and gastric cancer
([2,4,6,8,10]. The role of R-spondin 2 in colon cancer represents a clear
example of these contradictory results, as it was reported to enhance
cancer progression by enriching LGR5+ stem cells; but at the same
time supress cancer progression through inhibitingWnt/β-Catenin sig-
nalling leading to a reduction in cancer cell proliferation andmetastases
formation [4,6,10]. This current article by Zhang et al. provides an in
depth view about the enhancing role of the R-Spondin 2-LGR4 system
in TSCC progression [9]. The evidence provided in this article are quite
strong, especially since it covers several aspects of tumour progression,
includes patient tissue samples, and in vitro and in vivo experiments. It is
important to note that the authors showed that a high Rspo2 expression
associated signiﬁcantly with lymph node metastasis. This is anDOI of original article: https://doi.org/10.1016/j.ebiom.2019.03.076.
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gional lymphnodes followed by dissemination of the cancer and distant
metastases formation. This observation could, together with the up-
regulation of the epithelial-mesenchymal transition (EMT) properties
by Rspo2, function as a driving force for the migratory and invasive be-
haviour of TSCC, as suggested by the authors.
Combining together all of the data provided in this article, it is clear
that the Rspo2-LGR4 system participates in TSCC progression through
ﬁve different ways. It enhances proliferation, migration, invasion, EMT
and stem-like properties of cancer cells. The study also represents an
important advance in understanding the molecular mechanism behind
the role of the Rspo2-LGR4 system in TSCC progression, as the authors
investigated the signalling pathways underlying this system. Supported
by previous publications, the authorswere able to prove that the Rspo2-
LGR4 system works through the Wnt/β-catenin signalling pathway
[7,8].
One of themain questions which remains unanswered and requires
further profound study is the role of the Rspo2-LGR4 system inmetasta-
ses formation of the SCC cells - this needs to be tested in vivo. In the
newly accepted article by Zhang et al. a murine ectopic tumour xeno-
graft model was used to demonstrate the effect of Rspo2-LGR4 system
on tumour growth and cell proliferation [9]. Neither local invasion nor
metastases formationwere studiedhere, probably due to the limitations
of this model which does not usually allow cancer cells to spread or en-
able metastatic growth. It will be interesting to analyse metastasis
in vivo by using, for example, a murine orthotopic xenograft model
where TSCC cells are injected into the tongue and carcinoma cells in
neck lymph nodes are analysed. Additionally, a novel zebraﬁsh larvae
model could be used where TSCC cells are injected into the perivitelline
space and metastatic cells are also detected in the tail.
From a clinical point of view, the current work reveals a novel mol-
ecule and a possible target for therapeutic purposes. Although the trans-
lational process from in vitro testing to clinical use is very long and has a
high rate of failure - only 5% of compounds showing efﬁcacy in in vitro
tests were licensed following clinical trials [5] - the current study pro-
vides a stable base aiming to provide a new targeted therapy for TSCC
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